Philips and Biomérieux have signed an agreement to jointly develop fully automated handheld diagnostic devices that can be deployed at point of care in hospitals.
According to Philips, a product-development programme is underway and the first milestone is expected in 2010. As part of the agreement, Biomérieux will have access to Philips’ proprietary Magnotech technology for hospital-based point-of-care testing applications, a market that is said to be growing at 10 per cent a year.
Products resulting from the partnership will be co-branded by Philips and Biomérieux, with Biomérieux being the exclusive distributor worldwide. The two companies intend to have products on the market by 2013.
‘Philips is convinced that point-of-care testing in hospital critical-care settings will play a major part in improving patient outcomes and reducing healthcare costs,’ said Steve Rusckowski, executive vice president and chief executive officer, Philips Healthcare.